Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

How And Why Genzyme And Alnylam Expanded Their Alliance

Feb 14 2014

Related Content

Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy

Nov 01 2006

Alnylam’s Comeback: RNAi Developer Partners With Sanofi/Genzyme

Jan 13 2014

Genzyme’s Asian Expertise Drives Alnylam Co-Development Pact For TTR Candidates

Oct 23 2012

The Alnylam Turnaround: What Changed Investors’ Minds?

Sep 12 2012

Regeneron/Sanofi’s Long-Term Alliances Begin Bearing Fruit

Apr 02 2012

Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results

Jul 11 2013

Related Companies

Sanofi Genzyme

Sanofi

Alnylam Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc.

Merck & Co., Inc.

Sirna Therapeutics

Merck & Co., Inc.

Ionis Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc.

Additional Topics

Deals BioPharmaceutical

More from Deal-Making

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window